The ApyraMed technology exploits a recombinant live biotherapeutic that promotes adaptive intestinal homeostasis. In cancer patients, it enhances immune system competence, whereas in dysbiosis safeguards the intestinal ecosystem.
to infection
and Apyrase mediated
ATP degradation
integrity and intestinal function
Technology
